# NovaLign Orthopaedics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novalign-orthopaedics

- Industry: Medical Devices & Equipment
- Headquarters: Memphis, US
- Website: www.novalign.com
- Total disclosed funding: $10M
- Latest round: Series B (Jul 31, 2007)
- Investors on record: 3

## About

NovaLign Orthopaedics, Inc. develops innovative orthopedic solutions aimed at improving patient outcomes through advanced surgical techniques and technologies.Founded in 2005 in Memphis, US, NovaLign Orthopaedics, Inc. focuses on orthopedic advancements. In February 2011, the company was acquired by Sonoma Orthopedic Products as part of a strategic realignment. The firm has completed 3 deals, raising a total of USD 10.00 mn, with the most recent funding round being a Series B on 11 February 2011, participated in by Accuitive Medical Ventures, SV Health Investors, and Versant Ventures. The company's current valuation stands at USD 19.84 mn.NovaLign Orthopaedics specializes in innovative technology solutions that enhance operational efficiency in orthopedic surgical procedures. Their offerings include advanced surgical tools and platforms designed specifically to tackle challenges in orthopedic surgeries, thus improving surgical outcomes and patient care. The company serves a range of healthcare providers, from outpatient surgical centers to large hospital networks, particularly within North America and Europe.The revenue model of NovaLign Orthopaedics is based on direct sales of surgical products and technology solutions, with opportunities for recurring revenue through service agreements. The company primarily engages in transactions with healthcare institutions, facilitating ongoing client relationships through reliable product performance and support. This structure supports a sustainable revenue stream as clients continue to invest in advanced surgical technologies.NovaLign Orthopaedics plans to expand its product line by launching new surgical tools and platforms designed to enhance specific orthopedic procedures, with product launches expected within the next 18 months. Additionally, the company aims to enter key markets in Europe and Asia by the end of 2023. The funds from the Series B round will be utilized to support these new product developments and market expansion efforts.

## Funding rounds

- Series B, Jul 31, 2007, $10M — Versant Ventures, Accuitive Medical Ventures, SV Health Investors
- Seed, Jun 1, 2005 — SV Health Investors

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Seed, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B
- Accuitive Medical Ventures (https://capitalatlas.ai/funds/accuitive-medical-ventures) — Series B